SCHEMBL6489298

SCHEMBL6489298

Cc1ccc2c(c1)cc(-c1ccc(Br)cc1)n2C

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.46
MAPT P10636 2/20 0.45
RXFP1 Q9HBX9 2/20 0.45
MAOB P27338 2/20 0.44
CYP19A1 P11511 1/20 0.42
MCL1 Q07820 1/20 0.41
ACLY P53396 1/20 0.39
THRB P10828 1/20 0.39
ALDH1A1 P00352 1/20 0.39
APP P05067 4/20 0.38
SMPD1 P17405 1/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
KDM4E B2RXH2 1/20 0.38
PAX8 Q06710 1/20 0.37
ADORA2B P29275 1/20 0.37
MAOA P21397 1/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13444463 0.91 KMT2A (0.53) KMT2AMAPTRXFP1MAOBCYP19A1
SCHEMBL11686956 0.83 KMT2A (0.46) KMT2AMAPTRXFP1MAOBCYP19A1
SCHEMBL18470544 0.83 MAPT (0.49) KMT2AMAPTRXFP1CYP19A1THRB
SCHEMBL11662919 0.83 KMT2A (0.68) KMT2AMAPTRXFP1MAOBCYP19A1
SCHEMBL18470539 0.80 KMT2A (0.42) KMT2AMAPTRXFP1CYP19A1THRB
SCHEMBL8591982 0.79 KMT2A (0.73) KMT2AMAPTCYP19A1MCL1ALDH1A1
SCHEMBL2382803 0.78 KMT2A (0.66) KMT2AMAPTCYP19A1MCL1ALDH1A1
SCHEMBL22005143 0.75 ACLY (0.48) KMT2AMAPTRXFP1CYP19A1ACLY
SCHEMBL6478331 0.75 MAPT (0.62) MAPTRXFP1THRBALDH1A1NPC1
SCHEMBL3686929 0.74 KMT2A (0.76) KMT2AMAPTRXFP1CYP19A1MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014942-A1 Transforming growth factor inhibitor; controllign cell differentiation, cell proliferation NIPPON SHINYAKU CO., LTD. (JP) 2005-01-20 US disclosed
EP-1452525-A1 AMIDE DERIVATIVES AND DRUGS Nippon Shinyaku Co., Ltd. (JP) 2004-09-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014942-A1 Transforming growth factor inhibitor; controllign cell differentiation, cell proliferation TGFBR1, TGFBR2, TGFB1 KMT2A 1575/4885MAPT 4750/4885RXFP1 136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.